Early Toxicology: Markets and Approaches

Attention: There is an updated edition available for this report.
   Single User - $3,995
   Site License (one location, 10 users) - $5,995
   Corporate License - $7,990

Published Sep 12, 2012 | 180 Pages | Pub ID: KLI4873387

Early toxicology testing is emerging as one of the mostsignificant areas of drug discovery. Toxicity is no longer something that can be left to the development stage, or just a small part of ADMET. Toxicity determinations are an integral part of all aspects of drug discovery & development. 

This report, Early Toxicology Markets and Approaches, focuses on markets for early toxicology testing services. The objective of this report is to focus the reader’s attention on the issues and opportunities related to early toxicology testing in drug discovery. It begins with an overview of drug discovery, ADMET, and early toxicology testing. It continues with some of the ways big pharmaceutical developers dealwith early toxicology.  Several areas are covered, including:

For the purposes of reporting market size and growth forecasts, the report segments the market into the following:

  • In Silico Approaches
    • Databases
    • Data Mining Tools
    • Modeling
    In Vitro Assays and Platforms
    • Biochemical Assays
    • Cellular Assays
    • Instruments & Platforms
  • In Vivo Testing
    • Mice & Traditional Animals
    • Zebrafish Models
    • Other Animals
    • Human Microdosing
  • Early Tox Services
    • In Silico Services
    • In Vitro Services
    • In Vivo Services

Market analysis in this report considers primarily the availabilityof products, number and type of clinical trials active, primary endpoints, anddevelopment of new products.  The marketfocuses on the United States region and, where available, discusses the marketglobally. All sales are displayed at the manufacturers’ level in U.S.dollars.  Although the sales figures aredisplayed at the manufacturers’ level, in many instances, this figurerepresents a close comparison to the retail level as many end users arepurchasing directly from the manufacturer.The base year is 2011, with forecasts provided for each year through 2016.  

Early toxicology is done not only to discover problem compounds, but provide directions for compound development. Early toxicology gives more than just a yes/no answer. It provides predictions of how the compound will interactwith cells, tissues, organs, systems, and the whole human. It can also show howa cell responds to a candidate compound.   Various in vivo, in vitro, and in silico approaches have been evolving ever since. The objective of this report is to focus the reader’s attention on the issues and opportunities related to early tox testing in drug discovery, including:

  • Market Size of Segments and Subsegments within Toxicology
  • Forecasts of Expected Future Revenue Growth
  • Review of R&D Spending Trends 
  • Discussion of Various Big Pharma Approaches to Early Toxicology Testing
  • Consideration of Emerging Tools and Techniques
  • Revenues of Top Toxicology Service Companies
  • The Views of Interviewed Experts in the Field 
  • The Key Competitors and their Product and Service Offerings.
At first glance, drug discovery can appear to be a straightforward process of screening compound candidates, optimizing leads, performing pre-clinical evaluations and then, with these steps completed, clinical trials can begin. The reality is not so neat. These activities often overlap, merge, and conflict with each other. So ADME (Absorption, Distribution, Metabolism, Excretion) and Toxicology are not simply a step in lead optimization, they are actually an integral part of an ongoing process.

The report begins with an overview of drug discovery, ADMET, and early tox testing. It continues with some of the ways big pharmas deal with early tox. The next four chapters deal with the markets for in-silico, in-vitro, and in-vivo early tox products, and with the suppliers of early tox services. Product, company and market information are provided in each of these chapters. Opinions of the experts on basic issues are provided in Chapter Seven. The report concludes with profiles of 30 representative suppliers, the products they provide and their approach to the market.

As part of the report's detailed coverage, the following companies are profiled:
  • Accelrys
  • Albany Molecular
  • BD Biosciences
  • Beckman Coulter
  • Bio-Rad
  • Caliper Life Sciences
  • CeeTox
  • Cellectis
  • Cellomics
  • Charles River
  • Covance
  • Entelos
  • GE Biosciences
  • Gene Logic
  • IDBS
  • Ingenuity Systems
  • Life Technologies (Invitrogen)
  • Phylonix
  • Promega
  • Simulations Plus
  • Thermo Fisher
  • Xceleron
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times